Research suggests a monoclonal antibody may improve care for certain cases of non-small-cell lung cancer, with phase 3 data indicating potential benefits. Other emerging treatments, including bispecific antibodies and antibody-drug conjugates, are also being explored for lung cancer and other conditions. The landscape of lung cancer treatment appears to be evolving, with various new strategies and therapies being developed and tested.